Effects of Xerostom® products on xerostomia in primary Sjögren's syndrome: a randomised clinical trial

Abstract

Objectives

To assess the effects of Xerostom^® toothpaste and mouthwash in Primary Sjögren's syndrome (pSS) patients with xerostomia.

Subjects and Methods

A double‐blinded, randomized study where patients were assigned at baseline test or control products. Patients used the products 3 times/day/28 days. We used a Visual Analog Scale (VAS) for xerostomia and an Oral Health Impact Profile‐14 (OHIP‐14), baseline and after treatment, to assess possible improvement.

Results

A total of 28 patients with pSS were included in this study, but only 24 finished it (all women, mean age 55.21±11.87), 13 patients received the test and 11 the control. VAS and OHIP‐14 scores decreased in both groups after treatment but significant differences between groups were not found. We do not detect VAS intragroup significant differences before and after treatment in test and control groups. A significant improvement in OHIP‐14 was identified in the treatment group, while no significant differences were observed in the control group. No adverse effects were present.

Conclusions

Xerostom^® toothpaste and mouthrinse may alleviate and improve quality of life without associated side effects, but further research with a larger number of participants and follow‐up are necessary to establish the positive efficacy of these topical products in pSS patients.

This article is protected by copyright. All rights reserved.

https://ift.tt/2BtIXPs